DNM1L and diabetes mellitus: In contrast, MAP4K4 silencing, DMX-5804 treatment or the human Drp1 C644A mutation inhibited SNO-Drp1 and alleviated endothelial ferroptotic injury in diabetes, thereby improving cardiac microvascular disorders.